Luye Pharma Group (HKG:2186) has received marketing approval for Zepzelca from China's National Medical Products Administration, a Tuesday bourse filing said.
The drug is indicated for the treatment of adult patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy, according to the pharmaceutical company.